Shots:
- Novo Nordisk has reported a sub-analysis of P-III (REDEFINE 1) trial assessing cagrilintide monotx. (2.4mg) with lifestyle intervention vs PBO in 3,417 obese/overweight pts with ≥1 obesity-related comorbidities, & without type 2 diabetes
- Trial showed 11.8% superior weight loss vs 2.3% after 68wks., while 31.6% lost ≥15% of body weight vs 4.7%. However, weight loss was 11.5% vs 3%, with 31% vs 5.2% pts achieving ≥15% weight loss using treatment policy estimand. Data was presented at EASD’25
- Additionally, cagrilintide will be assessed in P-III (RENEW) trial programme for people with obesity or overweight by Q4’25
Ref: Novo Nordisk | Image: Novo Nordisk | Press Release
Related News:- Novo Nordisk Reports STEER Real-World Study Data on Wegovy for Obesity and Cardiovascular Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
